Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Unicycive Therapeutics, Inc.

Market Cap 191M 165M 152M 143M 268M 18.1B 271M 1.8B 699M 8.86B 718M 703M 30.72B P/E Ratio 2026 *
-7.34x
P/E Ratio 2027 * 1.12x
Enterprise Value 191M 165M 152M 143M 268M 18.1B 271M 1.8B 699M 8.86B 718M 703M 30.72B EV / Sales 2026 *
10.7x
EV / Sales 2027 * 0.55x
Free-Float
97.64%
Yield 2026 *
58.2%
Yield 2027 * 32.5%
1 day+0.70%
1 week-1.38%
Current month-2.85%
1 month-13.20%
3 months+2.28%
6 months+21.94%
Current year+24.26%
1 week 6.98
Extreme 6.98
8.06
1 month 6.65
Extreme 6.65
8.4
Current year 5.36
Extreme 5.36
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
87.3
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 17/08/2016
Director of Finance/CFO 64 28/02/2021
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Chairman 53 17/08/2016
Director/Board Member 58 31/12/2017
Director/Board Member 58 05/09/2023
Date Insider Type Main position Quantity % Market Cap.
05-13Free

Chief Operating Officer

169,500 0.6716%
05-13Free

Chief Financial Officer

169,500 0.6716%
05-13Free

Chief Executive Officer

762,200 3.0201%
Change 5-day change 1-year change 3-year change Capi.($)
+0.70%-1.38%-4.94%-50.89% 191M
-0.71%-0.29%+56.45%+107.18% 54.54B
-1.22%+5.01%+43.38%+36.69% 43.86B
-1.43%+3.47%-15.83%-20.48% 22.63B
-1.99%-3.55%-5.97%+377.60% 20.7B
-1.27%-0.20%+15.33%-36.53% 15.84B
-2.38%-3.38%+5.53%-41.88% 14.83B
-1.70%-1.68%+24.79%+172.92% 13.1B
-4.33%+1.44%+22.95% - 12.66B
+0.29%+5.10%+75.82%+105.33% 11.56B
Average -1.40%+1.79%+21.75%+72.22% 20.99B
Weighted average by Cap. -1.40%+1.41%+30.08%+86.60%

Financials

2026 *2027 *
Net sales 17.83M 15.37M 14.15M 13.29M 24.94M 1.69B 25.21M 167M 65.14M 826M 66.92M 65.5M 2.86B 346M 298M 275M 258M 484M 32.74B 489M 3.25B 1.26B 16.03B 1.3B 1.27B 55.56B
Net income -39.64M -34.16M -31.46M -29.53M -55.45M -3.75B -56.04M -372M -145M -1.84B -149M -146M -6.36B 225M 194M 179M 168M 315M 21.28B 318M 2.11B 822M 10.42B 845M 827M 36.11B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
16/06/26 7.170 $ +0.70% 1,109,501
15/06/26 7.120 $ -1.79% 1,038,380
12/06/26 7.250 $ -5.72% 953,919
11/06/26 7.690 $ 0.00% 682,382
10/06/26 7.690 $ +5.78% 1,030,233
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.170USD
Average target price
41.30USD
Spread / Average Target
+476.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!